WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) --

新泽西州沃伦，2026年10月8日（环球电讯社）--

Tevogen Inc.

泰沃根公司

(“Tevogen” or the “Company”) (Nasdaq:

（“Tevogen”或“公司”）（纳斯达克：

TVGN

电视指南网

), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”)..

），一家整合生物制药、人工智能和医疗服务以提升救命药物可负担性和可及性的综合医疗健康企业，今日宣布已签署一份非独家、无约束力的意向书（“LoI”），以评估与HRK Healthcare LLC（“HRK”）的潜在交易。

If consummated, the proposed transaction could expand Tevogen’s healthcare infrastructure capabilities and support the Company’s evolution into a revenue-generating healthcare enterprise comprised of Tevogen Bio, its biopharma arm; Tevogen.AI, its technology arm; and, subject to completion of proposed transactions, a healthcare services arm that may include management services..

若该拟议交易完成，将有助于扩大Tevogen在医疗健康基础设施方面的能力，并支持公司转型为一家创收型医疗健康企业。该企业将由Tevogen Bio（其生物制药板块）、Tevogen.AI（其技术板块）以及在拟议交易完成后可能包含管理服务在内的医疗服务板块组成。

“I am pleased with Tevogen’s continued progress toward building an integrated healthcare enterprise,” said Dr. Manmohan Patel, MD, Tevogen’s lead investor. “The potential HRK transaction represents an opportunity to expand the Company’s healthcare services capabilities and advance its mission of improving the affordability and accessibility of life-saving medicines.

“我对 Tevogen 在建设一体化医疗健康企业方面取得的持续进展感到满意，”Tevogen 的主要投资者 Manmohan Patel 医学博士表示。“潜在的 HRK 交易为公司提供了一个机会，以扩展其医疗服务能力，并推进其提高救命药物可负担性和可及性的使命。”

If consummated, this opportunity, together with other strategic acquisition initiatives, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue.”.

如果成功完成，此次交易连同其他战略收购举措，有望为Tevogen开辟道路，实现约1亿美元的合并年收入。

The proposed transaction remains subject to, among other things, completion of due diligence, negotiation and execution of definitive documentation, required approvals, and satisfaction of customary closing conditions.

拟议交易仍须完成尽职调查、谈判并签署最终文件、获得所需批准以及满足惯常的交割条件等事项。

Tevogen is also actively considering other transactions with a focus on life sciences and healthcare-related businesses; however, there can be no assurance that any such transaction will be consummated.

Tevogen 也在积极考虑其他以生命科学和医疗保健相关业务为重点的交易；然而，无法保证任何此类交易将会完成。

About Tevogen

关于泰沃根

Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: Tevogen Bio, its biotechnology initiative; Tevogen.AI, its artificial intelligence and technology initiative; and Tevogen Healthcare Services, its emerging healthcare services initiative..

Tevogen 是一家致力于提高救命药物可负担性和可及性的医疗健康企业。该公司整合了三项互补的业务板块：Tevogen Bio（其生物技术业务）、Tevogen.AI（其人工智能与技术业务）以及 Tevogen Healthcare Services（其新兴的医疗服务业务）。

Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.

这些举措共同旨在构建一个更加整合的医疗模式，使科学、技术与运营效率协同作用，从而降低药品成本并扩大患者的用药可及性。

Forward Looking Statements

前瞻性陈述

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transaction and the potential benefits of the transaction; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer.

本新闻稿包含某些前瞻性陈述，包括但不限于以下方面的陈述：潜在交易及该交易的潜在益处；Tevogen 对其研发和制造能力的规划；对未来增长的预期；对医疗保健和生物制药行业的预期；以及 Tevogen 针对传染病和癌症治疗的产品候选物的开发、其潜在益处及患者获取情况。

Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements..

前瞻性陈述有时可以通过“可能”、“能够”、“将会”、“预期”、“预计”、“有可能”、“潜在”、“目标”、“机会”、“预测”、“相信”、“未来”等词语及类似表述或其反义词来识别。这些陈述基于管理层在本新闻稿发布之日的预期、假设、估计、预测和信念，并受多种因素影响，其中包括已知和未知的风险、延迟、不确定性以及公司无法控制的其他因素，这些因素可能导致公司的实际结果、业绩或成就与这些前瞻性陈述所表达或暗示的结果、业绩或预期存在重大差异。

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transaction; the risk that the transaction may not be consummated on favorable terms or at all; the risk that the expected benefits of the transaction may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; ri.

可能导致实际结果、业绩或成就与前瞻性陈述所明示或暗示的内容存在差异的因素包括但不限于：拟议交易的尽职调查和谈判中固有的风险；交易可能无法以有利条款完成或根本无法完成的风险；交易预期利益可能无法及时实现或根本无法实现的风险；Tevogen 所在市场的变化，包括竞争格局、技术演变或监管政策的变化；国内及全球总体经济状况的变化；Tevogen 可能无法执行其增长战略，或在管理增长和扩张业务时遇到困难的风险；Tevogen 可能无法建立并维持有效内部控制的风险；未能实现 Tevogen 的商业化和发展计划，以及未能识别并把握额外机会的风险，这些可能受到竞争、Tevogen 以经济高效方式增长和管理增长的能力、以及招聘和留住关键员工的能力等因素的影响；Tevogen 可能无法跟上快速的技术发展以提供新颖创新的产品和服务，或对不成功的新产品和服务进行大量投资的风险；Tevogen 需要筹集额外资本以全面实施其业务计划的风险；与开发、许可或收购新疗法相关的风险；与 Tevogen 业务相关的监管诉讼或程序的风险；临床前研究和临床试验的执行、成本和完成过程中固有的不确定性；与监管审查、批准及商业化开发相关的风险；ri.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

您不应过度依赖前瞻性陈述，这些陈述仅在其发表之日有效。Tevogen 没有义务更新任何前瞻性陈述，除非适用法律另有要求。

Contacts

联系人

Tevogen Bio Communications

Tevogen Bio 通讯

T: 1 877 TEVOGEN, Ext 701

电话：1 877 TEVOGEN，分机 701

Communications@Tevogen.com

Communications@Tevogen.com